Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.7000
+0.0217 (3.20%)
At close: Jun 6, 2025, 4:00 PM
0.6999
-0.0001 (-0.01%)
After-hours: Jun 6, 2025, 7:31 PM EDT

Xilio Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-54.3-58.24-76.4-88.22-75.8-55.22
Upgrade
Depreciation & Amortization
1.71.641.91.851.51.07
Upgrade
Loss (Gain) From Sale of Assets
00000.02-
Upgrade
Stock-Based Compensation
6.146.437.388.424.961.3
Upgrade
Other Operating Activities
--0.160.220.380.17
Upgrade
Change in Accounts Payable
1.241.53-2.060.49-2.822.93
Upgrade
Change in Unearned Revenue
39.8732.78----
Upgrade
Change in Other Net Operating Assets
26.46-2.520.411.52-8.9913.68
Upgrade
Operating Cash Flow
21.1-18.38-68.62-75.72-80.75-36.09
Upgrade
Capital Expenditures
-0.06-0.04-0.49-1.87-1.1-2.19
Upgrade
Investing Cash Flow
-0.06-0.04-0.49-1.87-1.1-2.19
Upgrade
Long-Term Debt Issued
----0.98-
Upgrade
Long-Term Debt Repaid
--3.38-6.75-0.09-1.09-0.1
Upgrade
Net Debt Issued (Repaid)
-0.03-3.38-6.75-0.09-0.11-0.1
Upgrade
Issuance of Common Stock
33.132.580.20.02116.640.16
Upgrade
Other Financing Activities
-----0.75-0.03
Upgrade
Financing Cash Flow
33.0729.2-6.55-0.07260.6710.03
Upgrade
Net Cash Flow
54.1210.78-75.66-77.66178.82-28.25
Upgrade
Free Cash Flow
21.04-18.41-69.11-77.59-81.85-38.28
Upgrade
Free Cash Flow Margin
226.91%-290.26%----
Upgrade
Free Cash Flow Per Share
0.32-0.34-2.51-2.83-14.60-73.08
Upgrade
Cash Interest Paid
-0.060.570.560.490.54
Upgrade
Levered Free Cash Flow
19.13-16.29-42.32-45.9-52.31-19.43
Upgrade
Unlevered Free Cash Flow
19.19-16.23-41.88-45.4-51.94-19.05
Upgrade
Change in Net Working Capital
-47.02-13.011.22-1.9110.39-14.88
Upgrade
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q